SCHEMBL13443592

SCHEMBL13443592

Cc1ccc(-n2c3ccccc3c3cc(-c4ccc(-c5ccc6c(c5)C(C)(C)c5cc(-c7ccc(-c8ccc9c(c8)c8ccccc8n9-c8ccc(C)cc8)c8ccccc78)ccc5-6)c5ccccc45)ccc32)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ ATM Q13315 1/20 0.38
▸ AKR1C4 P17516 1/20 0.36
▸ AKR1C3 P42330 1/20 0.36
▸ AKR1C2 P52895 1/20 0.36
▸ AKR1C1 Q04828 1/20 0.36
▸ PDK2 Q15119 1/20 0.35
▸ LMNA P02545 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ RXFP1 Q9HBX9 2/20 0.34
▸ HDAC4 P56524 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ PGR P06401 1/20 0.33
▸ PTGER4 P35408 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ KMT2A Q03164 1/20 0.32
▸ PARP1 P09874 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13443611 0.96 KDM4E (0.39) KDM4EL3MBTL1ATMAKR1C4AKR1C3
SCHEMBL13443580 0.95 PDK2 (0.40) KDM4EL3MBTL1ATMAKR1C4AKR1C3
SCHEMBL13444529 0.94 KDM4E (0.44) KDM4EL3MBTL1ATMAKR1C4AKR1C3
SCHEMBL13444560 0.94 KDM4E (0.44) KDM4EL3MBTL1ATMAKR1C4AKR1C3
SCHEMBL13444508 0.93 KDM4E (0.43) KDM4EL3MBTL1ATMAKR1C4AKR1C3
SCHEMBL13444301 0.93 KDM4E (0.43) KDM4EL3MBTL1ATMAKR1C4AKR1C3
SCHEMBL13444410 0.93 KDM4E (0.43) KDM4EL3MBTL1ATMAKR1C4AKR1C3
SCHEMBL24496566 0.92 PDK2 (0.38) KDM4EL3MBTL1ATMAKR1C4AKR1C3
SCHEMBL13444542 0.92 KDM4E (0.42) KDM4EL3MBTL1ATMAKR1C4AKR1C3
SCHEMBL13443598 0.92 PDK2 (0.36) KDM4EL3MBTL1ATMAKR1C4AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100066241-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-03-18 — — US disclosed
US-20100066241-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-03-18 — — US disclosed
EP-2138551-A2 Fluorene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2009-12-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100066241-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same IL33, ORMDL3, CCND3 KDM4E 4343/4885L3MBTL1 482/4885ATM 4786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback